0000000000493888

AUTHOR

Thomas Woelfel

showing 9 related works from this author

Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial

2000

The ELISPOT assay is increasingly being used for the monitoring of the induction of antigen-reactive T cells in cancer vaccination trials. In order to evaluate the reliability of T cell frequency analysis with the ELISPOT assay, a comparative study was performed in four European laboratories. Six samples from healthy subjects were analyzed for the frequency of influenza-reactive CD8+ T cells in peripheral blood mononuclear cells (PBMC) by IFNgamma-ELISPOT assay. In addition, one laboratory determined cytotoxic T cell precursor (CTL) frequencies in these samples by limiting dilution chromium-release assay (LDA), and three laboratories performed a variant of the LDA, the multiple microculture…

T cellImmunologyEpitopes T-LymphocyteIndicator Dilution TechniquesEnzyme-Linked Immunosorbent AssayCD8-Positive T-LymphocytesLymphocyte ActivationPeripheral blood mononuclear cellViral Matrix ProteinsInterferon-gammaAntigenHLA-A2 AntigenHumansImmunology and AllergyCytotoxic T cellMedicineAntigens ViralImmunodominant Epitopesbusiness.industryELISPOTMolecular biologyChromium RadioisotopesHIV Reverse TranscriptasePeptide FragmentsCTL*medicine.anatomical_structureImmunologyLeukocytes MononuclearCancer vaccinebusinessCD8T-Lymphocytes Cytotoxic
researchProduct

29: Rapid expansion of acute myeloid leukemia-reactive cytotoxic T cells from CD8+CD62L+ blood lymphocytes of HLA-matched healthy donors in vitro

2007

Transplantationbusiness.industryRapid expansionCancer researchMyeloid leukemiaMedicineCytotoxic T cellHematologyHuman leukocyte antigenbusinessCD8In vitroBiology of Blood and Marrow Transplantation
researchProduct

Rapid Expansion of Acute Myeloid Leukemia-Reactive Cytotoxic T Cells from CD8+CD62L+ Blood Lymphocytes of HLA-Matched Healthy Donors In Vitro

2006

Abstract Allogeneic cytotoxic T-lymphocyte (CTL) therapy in acute myeloid leukemia (AML) is hampered by the poor efficiency of growing leukemia-reactive CTLs from healthy donors in vitro. We established an allogeneic mini-mixed lymphocyte-leukemia culture (MLLC) approach by stimulating comparably small numbers (104/well) of CD8+ T cells isolated from healthy donors against irradiated primary AML blasts in 96-well plates. Prior to use, CD8+ T cells were immunomagnetically separated into a CD62L(high)+ subset enriched for naive precursors and central memory cells as well as a CD62L(low)+/negative subset containing effector memory cells. The culture medium contained IL-7, IL-12, and IL-15. Aft…

ELISPOTImmunologyMyeloid leukemiaCell BiologyHematologyHuman leukocyte antigenBiologyBiochemistryHaematopoiesisCTL*Antigenhemic and lymphatic diseasesImmunologyCytotoxic T cellCD8Blood
researchProduct

Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers.

2015

Abstract Previous cancer vaccination trials often aimed to activate CD8+ cytotoxic T-cell (CTL) responses with short (8–10mer) peptides and targeted CD4+ helper T cells (TH) with HLA class II–binding longer peptides (12–16 mer) that were derived from tumor antigens. Accordingly, a study of immunomonitoring focused on the detection of CTL responses to the short, and TH responses to the long, peptides. The possible induction of concurrent TH responses to short peptides was widely neglected. In a recent phase I vaccination trial, 53 patients with different solid cancers were vaccinated with EMD640744, a cocktail of five survivin-derived short (9- or 10-mer) peptides in Montanide ISA 51VG. We m…

0301 basic medicineCD4-Positive T-LymphocytesCancer ResearchImmunologyOleic AcidsHuman leukocyte antigenCD8-Positive T-LymphocytesCancer VaccinesCell Line03 medical and health sciences0302 clinical medicineAntigenAdjuvants ImmunologicNeoplasmsCytotoxic T cellMedicineHumansAvidityMannitolbusiness.industryVaccinationCTL*030104 developmental biologyTreatment OutcomeImmunologyVaccines SubunitPeptide vaccinebusinessCD8030215 immunologyCancer immunology research
researchProduct

2004

Address: 1I. Medical Department, University of Mainz, Langenbeckstr.1, D-55101 Mainz, Germany, 2Deutsches Krebsforschungszentrum, Applied Tumor Virology, Dept. F0100, and Institut National de la Sante et de la Recherche Medicale Unite 375, Im Neuenheimer Feld 242, D-69120 Heidelberg, Germany, 3III. Medical Department, University of Mainz, Langenbeckstr.1, D-55101 Mainz, Germany and 4Med. Department Mitte, Klinikum Dortmund GmbH, Beurhausstr. 10, 44137 Dortmund, Germany

Cancer ResearchbiologyFollicular dendritic cellsParvovirusbusiness.industryAntigen presentationbiology.organism_classificationVirologyMedical departmentImmune systemOncologyImmunologyGeneticsTumor cell deathMedicineAntigen-presenting cellbusinessCancer Cell International
researchProduct

Peptides from NM23B - A Transcription Factor with NDP Kinase Activity - Are Expressed on the Surface of Leukemic Cells and Are Recognized by T-Lympho…

2005

Abstract Objective: During the last years a growing number of MHC-restricted antigens were recognized using autologous or HLA-matched cytotoxic T-cell lines (TCL). Molecules were isolated by HPLC or identified using cDNA expression cloning from normal or malignant target cells and found to derive from normal proteins or from mutated tumor-specific proteins. The majority of the tumor-specific peptides were derived from melanoma cells. The aim of this project was to search for immunogenic peptides on leukemia cells with the help of TCLs obtained from a stem cell donor against chronic myelogenous leukaemia (CML) recipient cells and to identify the immunogenic peptides by cDNA expression clonin…

cDNA libraryELISPOTImmunologyCell BiologyHematologyHuman leukocyte antigenTransfectionBiologyBiochemistryMolecular biologyAntigenComplementary DNACytotoxic T cellKinase activityBlood
researchProduct

Graft-Versus-Host Disease or Infection: Rapid Detection of HLA Mismatch-Reactive T Cells Ex Vivo Can Facilitate Diagnosis and Guide Therapy after All…

2007

Abstract Diagnosis of graft-versus-host disease (GVHD) is mainly based on clinical features and on tissue biopsies. However, clinicians and pathologists are well aware of cases, in which GVHD cannot be distinguished from infections arising from severe immunodeficiency after allogeneic stem-cell transplantation (SCT). This may pose a deep therapeutic dilemma of whether to modify immunosuppressive treatment or to use donor lymphocyte infusion (DLI) for promoting anti-microbial immunity. We observed a 68-year-old patient with myelodysplastic syndrome who developed acute GVHD grade II of skin and gut at d+16 after T-cell depleted reduced-intensity SCT (Fig. 1). GVHD was confirmed by histology a…

business.industryT cellmedicine.medical_treatmentImmunologyImmunosuppressionCell BiologyHematologyHuman leukocyte antigenmedicine.diseaseBiochemistryHLA MismatchDonor lymphocyte infusionTransplantationGraft-versus-host diseasemedicine.anatomical_structureImmunologymedicinebusinessImmunodeficiencyBlood
researchProduct

Parvovirus H-1-Induced Tumor Cell Death Enhances Human Immune Response In Vitro via Increased Phagocytosis, Maturation, and Cross-Presentation by Den…

2005

Oncotropic and oncolytic viruses have attracted high attention as antitumor agents because they preferentially kill cancer cells in vitro and reduce the incidence of spontaneous, induced, or implanted animal tumors. Some autonomous parvoviruses (H-1, minute virus of mice) and derived recombinant vectors are currently under preclinical evaluation. Still not fully understood, their antitumor properties involve more than just tumor cell killing. Because wild-type parvovirus-mediated tumor cell lysates (TCLs) may trigger antigen-presenting cells (APCs) to augment the host immune repertoire, we analyzed phagocytosis, maturation, and crosspresentation of H-1-induced TCLs by human dendritic cells …

Skin NeoplasmsParvovirus H-1ApoptosisBiologyParvovirusMiceImmune systemCross-PrimingAntigenPhagocytosisAntigens NeoplasmHLA-A2 AntigenTumor Cells CulturedGeneticsCytotoxic T cellAnimalsHumansMelanomaMolecular BiologyCryopreservationCross-presentationCell DifferentiationDendritic cellDendritic CellsOncolytic virusCancer cellImmunologyCancer researchMolecular MedicineT-Lymphocytes CytotoxicHuman Gene Therapy
researchProduct

Lentivirus-induced dendritic cells for immunization against high-risk WT1(+) acute myeloid leukemia.

2013

Wilms' tumor 1 antigen (WT1) is overexpressed in acute myeloid leukemia (AML), a high-risk neoplasm warranting development of novel immunotherapeutic approaches. Unfortunately, clinical immunotherapeutic use of WT1 peptides against AML has been inconclusive. With the rationale of stimulating multiantigenic responses against WT1, we genetically programmed long-lasting dendritic cells capable of producing and processing endogenous WT1 epitopes. A tricistronic lentiviral vector co-expressing a truncated form of WT1 (lacking the DNA-binding domain), granulocyte-macrophage colony-stimulating factor (GM-CSF), and interleukin-4 (IL-4) was used to transduce human monocytes ex vivo. Overnight transd…

Genes Wilms TumorCell SurvivalGenetic VectorsAntineoplastic AgentsBiologyCD8-Positive T-LymphocytesLymphocyte ActivationPeripheral blood mononuclear cellEpitopeMonocytesViral vectorMiceAntigenRisk FactorsGeneticsmedicineNeoplasmAnimalsHumansMolecular BiologyResearch ArticlesOligonucleotide Array Sequence AnalysisCD86LentivirusGene Transfer TechniquesMyeloid leukemiaGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationDendritic CellsGenetic Therapymedicine.diseaseAdoptive TransferLeukemia Myeloid AcuteGene Expression RegulationCancer researchLeukocytes MononuclearMolecular MedicineInterleukin-4Ex vivoHuman gene therapy
researchProduct